Track record · closed signal

Johnson & Johnson (JNJ) — closed signal from December 5, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on March 5, 2026 — +17.9% at the close.

Predicted vs. what happened

JNJ price · publication thesis → realized outcomesplit-adjusted

$198.00 – $205.00Entry zone — fair-value band

$203.27Published — price the day we called it

$223.59Target — the price the thesis aimed for

$251.71Peak — highest point inside the window, not a realized return

$239.63Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 53 days.

At window close

+17.9%

realized, from the publication price to the last close inside the window

Peak gain

+23.8%

peak, from the publication price — not a realized return

S&P 500, same window

-0.3%

SPY over the identical days, dividend-adjusted

Window close

$239.63

last close inside the window, ended March 5, 2026

Peak price

$251.71

peak on March 2, 2026 — not a realized return

Days to target

The thesis — published December 5, 2025

Predicted growth

+10%

over the measurement window

Target price

$223.59

the price the thesis aimed for

Entry zone

$198.00 – $205.00

the fair-value band we waited for

Price at publication

$203.27

published December 5, 2025

Confidence

66%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

JNJ is a large, defensive healthcare company that has been sold down recently and now shows signs typical of stocks ready for a bounce. Analyst and Zacks commentary say expectations are modest, so you could see a small rebound over the next three months with limited downside versus riskier names.

Primary drivers

Indicators show the stock has been sold heavily and now may rebound
Investor sentiment is strong even if business growth is modest
Reliable cash flow and dividend make it a defensive holding
Analysts expect steady performance but limited upside

How it played out

JNJ: target reached in 53 days

Lyra published JNJ on 2025-12-05 at $203.27, looking for 10% growth over a short-term window. The thesis pointed to a heavily sold stock that might rebound, strong investor sentiment, reliable cash flow and dividend support, and steady performance with limited upside.

Inside the window, the stock reached the $223.59 target in 53 days. It later peaked at $251.71 on 2026-03-02, with a 23.8% gain at the peak. It ended the window at $239.63. The thesis played out, and the move went beyond the target.

What happened during the window

On 2026-01-21, Johnson & Johnson reported fourth-quarter 2025 revenue of $24.6 billion and forecast 2026 revenue of $100.5 billion. Barron's also reported on 2026-01-21 that adjusted earnings were $2.46 a share and that the stock fell that day after the report.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All JNJ signals